394 related articles for article (PubMed ID: 29482777)
1. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
2. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
3. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.
Ciani O; Davis S; Tappenden P; Garside R; Stein K; Cantrell A; Saad ED; Buyse M; Taylor RS
Int J Technol Assess Health Care; 2014 Jul; 30(3):312-24. PubMed ID: 25308694
[TBL] [Abstract][Full Text] [Related]
4. The value of surrogate endpoints for predicting real-world survival across five cancer types.
Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
[TBL] [Abstract][Full Text] [Related]
5. Surrogate endpoints for overall survival in lung cancer trials: a review.
Fiteni F; Westeel V; Bonnetain F
Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
[TBL] [Abstract][Full Text] [Related]
6. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
7. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
8. Surrogate end points for overall survival in breast cancer trials: A review.
Fiteni F; Bonnetain F
Breast; 2016 Oct; 29():44-8. PubMed ID: 27400447
[TBL] [Abstract][Full Text] [Related]
9. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
10. Individual- and trial-level surrogacy in colorectal cancer.
Buyse M; Burzykowski T; Michiels S; Carroll K
Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
[TBL] [Abstract][Full Text] [Related]
11. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer.
Liang F; Zhang S; Wang Q; Li W
Crit Rev Oncol Hematol; 2018 Oct; 130():36-43. PubMed ID: 30196910
[TBL] [Abstract][Full Text] [Related]
12. Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
Cheng S; Cheung MC; Jiang DM; McDonald E; Arciero VS; Ezeife DA; Rahmadian A; Chambers A; Sabarre KA; Parmar A; Chan KKW
J Natl Compr Canc Netw; 2019 Dec; 17(12):1489-1496. PubMed ID: 31805528
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
Mushti SL; Mulkey F; Sridhara R
Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
[No Abstract] [Full Text] [Related]
14. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
Hua T; Gao Y; Zhang R; Wei Y; Chen F
BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
[TBL] [Abstract][Full Text] [Related]
15. Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials.
Wang X; Wang X; Hodgson L; George SL; Sargent DJ; Foster NR; Ganti AK; Stinchcombe TE; Crawford J; Kratzke R; Adjei AA; Kindler HL; Vokes EE; Pang H
Oncologist; 2017 Feb; 22(2):189-198. PubMed ID: 28188257
[TBL] [Abstract][Full Text] [Related]
16. Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer.
Elia EG; Städler N; Ciani O; Taylor RS; Bujkiewicz S
Cancer Epidemiol; 2020 Feb; 64():101665. PubMed ID: 31911395
[TBL] [Abstract][Full Text] [Related]
17. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.
Ciani O; Buyse M; Garside R; Peters J; Saad ED; Stein K; Taylor RS
J Clin Epidemiol; 2015 Jul; 68(7):833-42. PubMed ID: 25863582
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.
Harshman LC; Xie W; Moreira RB; Bossé D; Ruiz Ares GJ; Sweeney CJ; Choueiri TK
Cancer; 2018 Mar; 124(5):925-933. PubMed ID: 29266178
[TBL] [Abstract][Full Text] [Related]
19. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials.
Petrelli F; Tomasello G; Ghidini M; Lonati V; Passalacqua R; Barni S
HPB (Oxford); 2017 Nov; 19(11):944-950. PubMed ID: 28764887
[TBL] [Abstract][Full Text] [Related]
20. Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review.
Branchoux S; Bellera C; Italiano A; Rustand D; Gaudin AF; Rondeau V
Crit Rev Oncol Hematol; 2019 May; 137():35-42. PubMed ID: 31014514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
